pembrolizumab,docetaxel
merck
['docetaxel', 'pembro', 'crpc', 'prostate', 'key,note,921']
#ascogu23 pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mcrpc): randomized, double-blind, phase 3 keynote-921 study. 
Medicina Interna - Oncología Clínica - Clínica Astorga. Profesor titular @upbcolombia #Medellín / #Colombia mlujanonco@gmail.com #OncTwitter #Metaanalysis